OncoMatch/Clinical Trials/NCT03089554
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Is NCT03089554 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Therapeutic Intervention for cancer.
Treatment: Therapeutic Intervention — This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received:
Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies.
Cannot have received: chemotherapy
Exception: within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Cannot have received: radiotherapy
Exception: within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Markey Cancer Center, University of Kentucky · Lexington, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify